Skip to main content

Liquid biopsies and Imaging for improved cancer care

Objective

LIMA’s overall objective is to develop and validate technologies and tools to include liquid biopsies in the clinical workflow, aiming at introducing a more precise and dynamic genetic characterization of tumor at the diagnosis and during treatment phases. This will be done by combining molecular information from liquid biopsies and direct in-vivo tumor characterization from advanced MR imaging, taking into account the current clinical workflow.
The LIMA project will be based on following 5 conceptual pillars:
1. A robust method to measure and genomically analyze ct-DNA for tumor-driving mutations, which can be measured in a quantitative manner allowing therapy response prediction and monitoring.
2. A workflow for Circulating Tumor Cell isolation and computational model-based quantitative signal pathway analysis on single CTC mRNA expression levels. This allows for assessment of tumor heterogeneity in pathway activity (to relate back to tumor heterogeneity), targeted therapy response prediction and monitoring
3. Correlation of computational, model-based cancer pathway activity assessment from cancer tissue samples before and after neoadjuvant treatment and from liquid biopsies with MR imaging features.
4. Advance in MR imaging to better probe and image the cancer lesion and its microenvironment
5. Clinical analysis, correlating liquid biopsy/imaging –based results to clinical outcome, that is the response to (targeted drug) neoadjuvant therapy in selected breast cancer and rectal cancer patients.
These 5 pillars will be investigated in longitudinal observational studies that will follow patients undergoing neoadjuvant treatment (either chemotherapy or targeted therapy or the combination) for primary rectal and breast cancer. LIMA will demonstrate that prediction of drug therapy response, monitoring of response and detection of resistance can be improved over the current state of the art.

Call for proposal

H2020-SC1-2017-Two-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

PHILIPS ELECTRONICS NEDERLAND BV
Address
High Tech Campus 52
5656 AG Eindhoven
Netherlands
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 813 093,75

Participants (9)

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 1 606 347,50
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
AGENA BIOSCIENCE GMBH
Germany
EU contribution
€ 517 742,50
Address
Gasstrasse 18, Haus 5
22761 Hamburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALS AUTOMATED LAB SOLUTIONS GMBH
Germany
EU contribution
€ 547 145
Address
Otto-eppenstein-strasse 30
07745 Jena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ANGLE EUROPE LIMITED
United Kingdom
EU contribution
€ 469 550
Address
Ground Floor 10 Nugent Road Surrey Research Park
GU2 7AF Guildford
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 1 077 563,75
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
STILLA TECHNOLOGIES
France
EU contribution
€ 483 532,50
Address
1 Mail Du Professeur Georges Mathe
94800 Villejuif
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PHILIPS GMBH
Germany
EU contribution
€ 265 795
Address
Rontgenstrasse 22
22335 Hamburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT REGIONAL DU CANCER DE MONTPELLIER
France
EU contribution
€ 398 070
Address
Rue De La Croix Verte 31 Parc Euromedecine
34090 Montpellier
Activity type
Research Organisations
DIADX
France
EU contribution
€ 114 033,75
Address
62 Chemin Des Combelles
34270 Les Matelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)